WALTHAM, Mass., July 24, 2026
Nova Biomedical has announced the acquisition of certain assets of NanoCellect, a recognized developer of microfluidic cell sorting technology, significantly expanding its capabilities in cell line development and strengthening its end-to-end support for biopharmaceutical research, process development, and manufacturing. The strategic addition integrates the NanoCellect® WOLF G2® cell sorting platform into Nova Biomedical’s growing Solentim® portfolio, creating a more comprehensive workflow that connects cell selection, single-cell isolation, clone verification, cell culture monitoring, and analytical process control. This milestone reinforces Nova Biomedical’s commitment to advancing bioprocessing innovation, enabling biopharmaceutical companies to accelerate the development of high-performing cell lines while improving productivity, reproducibility, and manufacturing efficiency across the entire biologics development lifecycle.
NanoCellect Integration Strengthens Cell Line Development Workflows
The addition of NanoCellect’s WOLF G2® platform significantly enhances Nova Biomedical’s ability to deliver an integrated solution for cell line development, one of the most critical stages in biopharmaceutical manufacturing. The microfluidic-based cell sorting technology provides gentle, sterile, and highly efficient cell selection and isolation, minimizing cellular stress while improving the quality of isolated clones. When combined with Nova’s established Solentim® technologies for single-cell cloning, clone verification, and growth analysis, the expanded platform enables researchers to streamline every step of clone development within a connected workflow. This integration supports faster identification of high-quality production cell lines, reduces workflow complexity, and improves consistency during clone selection. By linking upstream cell sorting with downstream analytical verification, Nova Biomedical provides researchers with enhanced confidence throughout the development process, helping accelerate biologics discovery while improving operational efficiency for biotechnology and pharmaceutical organizations.
Integrated Bioprocessing Portfolio Supports Faster Biopharmaceutical Manufacturing
Beyond cell line development, Nova Biomedical continues to strengthen its position in bioprocess analytics through a portfolio that includes BioProfile® FLEX2 for cell culture metabolite analysis, OsmoTECH® for osmolality measurement, and BioProfile® FAST CDV for cell counting and viability assessment. These technologies provide critical analytical data throughout process development, scale-up, manufacturing, and quality control, enabling biopharmaceutical manufacturers to maintain robust process performance while supporting regulatory compliance and product consistency. According to Nova Biomedical, integrating NanoCellect’s technologies creates a more connected ecosystem that enhances scientific decision-making, shortens cell line development timelines, and improves clone selection outcomes that ultimately influence manufacturing productivity. Company leadership emphasized that the acquisition represents a key milestone in building a differentiated platform capable of supporting the growing complexity of modern biologics development, including monoclonal antibodies, recombinant proteins, gene therapies, and cell therapies.
Advertisement
Strategic Expansion Advances Next-Generation Bioprocessing Innovation
The acquisition of selected NanoCellect assets reflects Nova Biomedical’s long-term strategy to build an integrated technology portfolio supporting the complete bioprocessing lifecycle, from early-stage research through commercial manufacturing. As the global biopharmaceutical industry continues expanding investment in advanced biologics and next-generation therapeutics, demand for automated, connected, and data-driven workflows is increasing rapidly. By combining microfluidic cell sorting, clone verification, cell culture analytics, and manufacturing process monitoring within a unified platform, Nova Biomedical is positioning itself to help customers accelerate development timelines, improve manufacturing performance, and enhance product quality across complex biologics programs. The expanded portfolio also lays the foundation for greater workflow connectivity, improved analytical insights, and smarter decision-making throughout bioprocess development. This strategic expansion reinforces Nova Biomedical’s leadership in bioprocess technologies while providing biotechnology and pharmaceutical manufacturers with advanced tools that improve efficiency, scalability, and innovation across modern biologics production.
Source: Nova Biomedical press release
